{"id":"202204142542","sourceId":"dow-jones","sourceName":"Global News Select","providerName":"Dow Jones","title":"Valneva's Covid-19 Vaccine Gets Its First Approval in UK","publishedDate":"2022-04-14T03:00:00-05:00","body":[{"type":"p","contentObject":[{"type":"text","content":"\n  By Maitane Sardon ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"pre","contentObject":[{"type":"text","content":"\n ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"p","contentObject":[{"type":"text","content":"\n  Valneva SE's coronavirus vaccine has been granted regulatory approval by the U.K.'s Medicines and Healthcare products Regulatory Agency, the government said Thursday. ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"p","contentObject":[{"type":"text","content":"\n  The U.K.'s medicines regulator is the first in the world to approve the French biotech company's shot. ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"p","contentObject":[{"type":"text","content":"\n  With this type of vaccine, the virus is grown in a lab and made completely inactive so that it can't infect cells or replicate in the body but can still trigger an immune response, a process that is widely used in flu and polio vaccines, the U.K. government said. ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"p","contentObject":[{"type":"text","content":"\n  \"Our approval of the COVID-19 vaccine made by Valneva today follows a rigorous review of the safety, quality and effectiveness of this vaccine, and expert advice from the government's independent scientific advisory body, the Commission on Human Medicines,\" MHRA Chief Executive Dr. June Raine said. ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"p","contentObject":[{"type":"text","content":"\n  Valneva shares were halted on the Paris stock market on Thursday. ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"pre","contentObject":[{"type":"text","content":"\n ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"p","contentObject":[{"type":"text","content":"\n  Write to Maitane Sardon at maitane.sardon@wsj.com ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"pre","contentObject":[{"type":"text","content":"\n ","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"p","contentObject":[{"type":"text","content":"\n  (END) Dow Jones Newswires","gated":false}],"gated":false},{"type":"text","content":"\n","gated":false},{"type":"p","contentObject":[{"type":"text","content":"\n  April 14, 2022 04:00 ET (08:00 GMT)","gated":false}],"gated":false},{"type":"text","content":"\n\nCopyright (c) 2022 Dow Jones & Company, Inc.","gated":false}]}